{
    "ticker": "NKTX",
    "name": "Nkarta, Inc.",
    "description": "Nkarta, Inc. is an innovative biotechnology company focused on the development of engineered natural killer (NK) cell therapies for the treatment of cancer. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to harness the power of the immune system to combat malignancies through its groundbreaking cell therapy platform. The company\u2019s proprietary NK cell technology allows for the creation of off-the-shelf therapies that can be administered to patients without the need for extensive pre-treatment. Nkarta is committed to making cell therapy accessible to a broader range of patients and is dedicated to advancing its pipeline of therapeutic candidates. The company's lead product candidates include NKX101 and NKX019, both of which are designed to target various hematologic malignancies. With a strong emphasis on research and development, Nkarta collaborates with leading institutions to push the boundaries of immunotherapy. By focusing on enhancing the efficacy and safety of NK cell therapies, Nkarta is positioned to play a transformative role in the oncology landscape, striving to provide hope to patients facing challenging cancers. The company is driven by a mission to improve patient outcomes and offer new solutions in the fight against cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.nkartainc.com",
    "ceo": "Paul J. Hastings",
    "social_media": {
        "twitter": "https://twitter.com/nkartainc",
        "linkedin": "https://www.linkedin.com/company/nkarta-inc/"
    },
    "investor_relations": "https://investors.nkartainc.com",
    "key_executives": [
        {
            "name": "Paul J. Hastings",
            "position": "CEO"
        },
        {
            "name": "Stacey C. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "NK Cell Therapies",
            "products": [
                "NKX101",
                "NKX019"
            ]
        }
    ],
    "seo": {
        "meta_title": "Nkarta, Inc. | Engineered NK Cell Therapies for Cancer Treatment",
        "meta_description": "Learn about Nkarta, Inc., a biotechnology company developing innovative NK cell therapies to treat cancer. Explore our pipeline and mission to improve patient outcomes.",
        "keywords": [
            "Nkarta",
            "NK Cell Therapy",
            "Cancer Treatment",
            "Immunotherapy",
            "Biotechnology",
            "NKX101",
            "NKX019"
        ]
    },
    "faq": [
        {
            "question": "What does Nkarta focus on?",
            "answer": "Nkarta focuses on developing engineered natural killer cell therapies for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Nkarta?",
            "answer": "Paul J. Hastings is the CEO of Nkarta, Inc."
        },
        {
            "question": "Where is Nkarta headquartered?",
            "answer": "Nkarta is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Nkarta's main products?",
            "answer": "Nkarta's main product candidates include NKX101 and NKX019."
        },
        {
            "question": "When was Nkarta founded?",
            "answer": "Nkarta was founded in 2015."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "ZBIO",
        "BEAM"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "JNJ",
        "GILD"
    ]
}